Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Maze Therapeutics (Nasdaq: MAZE) announced that CEO Jason Coloma, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT.

A live webcast will be available in the Investors section of Maze Therapeutics' website at www.mazetx.com, and the presentation will be archived for 30 days following the event.

News Market Reaction

-2.87%

1 alert

-2.87% News Effect

On the day this news was published, MAZE declined 2.87%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference date: January 12, 2026 Presentation time: 8:15 a.m. PT Webcast archive period: 30 days

3 metrics

Conference date January 12, 2026 J.P. Morgan Healthcare Conference presentation date

Presentation time 8:15 a.m. PT Scheduled start time for conference presentation

Webcast archive period 30 days Duration webcast will remain available after presentation

Market Reality Check

Price: $43.58 Vol: Volume 436,643 vs 20-day ...

normal vol

$43.58 Last Close

Volume Volume 436,643 vs 20-day average 465,475 suggests activity near typical levels pre-announcement. normal

Technical Shares at $39.77, trading above 200-day MA of $20.34 and 8.13% below 52-week high of $43.29.

Peers on Argus

Several biotech peers showed weakness (e.g., RAPP -6.46%, WVE -6.29%, SION -5.43...

Several biotech peers showed weakness (e.g., RAPP -6.46%, WVE -6.29%, SION -5.43%, ORIC -0.85%), while ELVN was slightly positive at +0.26%, pointing to mixed, stock-specific moves rather than a unified sector trend.

Common Catalyst At least one peer, SION, also issued a J.P. Morgan Healthcare Conference participation announcement, indicating a conference-related news theme among select biotechnology names.

Historical Context

5 past events · Latest: Nov 06 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 06	Q3 2025 earnings	Negative	-3.5%	Higher R&D and G&A drove net loss despite strong cash runway and pipeline data.
Nov 06	Clinical data update	Positive	-2.1%	Additional MZE782 and MZE829 data at ASN Kidney Week signaled advancing kidney programs.
Nov 04	Investor conferences	Neutral	-2.5%	Management participation in multiple investor conferences to highlight strategy and programs.
Oct 06	Chairman appointment	Positive	+1.5%	Appointment of experienced chairman alongside recap of financing and 2026 clinical milestones.
Sep 11	Private placement	Positive	+54.8%	Oversubscribed <b>$150.0 million</b> private placement at a premium to fund key programs.

Pattern Detected

Recent news often coincided with either modest declines after scientific or corporate updates, while financing and capital-related announcements like the oversubscribed $150.0 million private placement saw a strong positive reaction.

Recent Company History

Over the last several months, Maze highlighted strengthening finances and pipeline progress. Q3 2025 results showed a net loss of $96.6 million year‑to‑date but cash of $383.9 million, supported by an IPO and an oversubscribed $150.0 million private placement. Clinical updates for MZE782 and MZE829, plus multiple conference presentations, underscored focus on APOL1‑mediated kidney disease and PKU/CKD. Today’s J.P. Morgan conference participation fits the pattern of active investor and scientific engagement following 2025 financing and leadership changes.

Market Pulse Summary

This announcement adds another visibility event as Maze presents at the 44th Annual J.P. Morgan Heal...

Analysis

This announcement adds another visibility event as Maze presents at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. Investors following the story may focus on any new color around its kidney and metabolic disease pipeline, building on 2025 clinical updates and financings. Key items to watch include progress in planned Phase 2 trials, cash runway utilization, and how management frames upcoming data and regulatory milestones.

Key Terms

small molecule, precision medicines

2 terms

small molecule medical

"a clinical-stage biopharmaceutical company developing small molecule precision medicines"

A small molecule is a low-weight chemical compound that can enter cells easily and interact with specific proteins or biological pathways to change how they work, much like a small key fitting into a lock. Investors care because small molecules are a common and often faster route to develop medicines, can be manufactured at scale, and may offer clearer regulatory and commercial paths compared with larger biologic therapies, affecting potential costs, timelines and returns.

precision medicines medical

"developing small molecule precision medicines for patients with kidney and metabolic diseases"

Precision medicines are treatments designed to work for specific groups of patients identified by genetic, biological, or lifestyle characteristics, rather than a one-size-fits-all drug. They matter to investors because these therapies can be more effective and command premium pricing in smaller, well-defined markets—offering higher potential returns if successful but also concentrated development and regulatory risk, like betting on a tailored suit that fits only certain people.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the 44^th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT.

A live webcast of the event will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 30 days following the presentation.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases, including obesity. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor advancing to Phase 2 with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow the company on LinkedIn and X.

IR/Corporate Contact:
Amy Bachrodt, Maze Therapeutics
abachrodt@mazetx.com

Media Contact:
Amanda Lazaro, 1AB Media
Amanda@1ABMedia.com

FAQ

When will Maze Therapeutics (MAZE) present at the J.P. Morgan Healthcare Conference?

Maze Therapeutics CEO Jason Coloma will present on January 12, 2026 at 8:15 a.m. PT.

How can investors watch the Maze Therapeutics (MAZE) presentation on January 12, 2026?

A live webcast will be available in the company's Investors section at www.mazetx.com.

Will the Maze Therapeutics (MAZE) webcast be available after the J.P. Morgan presentation?

Yes. The presentation will be archived for 30 days after the event on the company's investor website.

Who is representing Maze Therapeutics (MAZE) at the 44th Annual J.P. Morgan Healthcare Conference?

Jason Coloma, Ph.D., the company's chief executive officer, will present.

What topics will Maze Therapeutics (MAZE) cover in the January 12, 2026 presentation?

The announcement confirms the presentation and webcast but does not disclose specific presentation topics or materials.